Results 181 to 190 of about 3,046 (215)

New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Cardiovascular & Hematological Agents in Medicinal Chemistry, 2023
Abstract: Obstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy, which eventually obstructs the outflow of the left ventricle. Obstructive hypertrophic cardiomyopathy is linked to mutations in genes that encode for sarcomere proteins, including actin, β-myosin heavy chain, titin, and troponin.
Rami A. Al-Horani, Ma’Lik Woodland
openaire   +2 more sources

Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for up to 128 Weeks: Insights From the VALOR-HCM Trial.

JACC Cardiovascular Imaging
BACKGROUND In the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy; NCT04349072) trial, patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM ...
M. Desai, Y. Okushi, K. Wolski, J. Geske, A. Owens, Qiu-Qing Wang, S. Saberi, Andrew Wang, Paul C Cremer, N. Lakdawala, M. Sherrid, A. Tower-Rader, D. Fermin, Mark A. Zenker, S. Naidu, K. Lampl, Steve E. Nissen, Z. Popović   +17 more
semanticscholar   +1 more source

Evaluation of mavacamten in patients with hypertrophic cardiomyopathy

Journal of Cardiovascular Medicine
Aims We aimed to comprehensively assess the safety and efficacy of mavacamten in hypertrophic cardiomyopathy (HCM) patients. Methods A systematic review and meta-analysis was conducted, and efficacy [changes in postexercise left ventricular outflow tract (LVOT) gradient, left ...
Hui-Ling, Liao, Yi, Liang, Bo, Liang
openaire   +2 more sources

Real-World Assessment of Mavacamten's Impact on Left Ventricular Systolic and Diastolic Functions in Obstructive Hypertrophic Cardiomyopathy: A 1-Year Single-Center Observational Study.

American Journal of Cardiology
Real-world data on the effects of mavacamten on diastology and global longitudinal strain (GLS) in symptomatic patients with obstructive hypertrophic cardiomyopathy (oHCM) are limited.
Z. Abood, M. Jan, M. Ashraf, Prabhjot Hundal, Lauren Howard, Heather Sanders, Amanda Misicka, Asad Ghafoor, Arshad Jahangir, Patrycja Z. Galazka, A. Tajik   +10 more
semanticscholar   +1 more source

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy

Clinical Therapeutics
Hypertrophic cardiomyopathy (HCM) is an under-recognized genetic cardiac disorder affecting the muscles and contractility of the heart, which in turn can result in heart failure symptoms, arrhythmia, and sudden cardiac death. Previously, pharmacotherapy options for HCM were not disease-specific, often poorly tolerated, and overall inadequate for ...
J. Chase Cole, Samantha F. Benvie, Marci DeLosSantos   +2 more
openaire   +2 more sources

Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center.

Progress in cardiovascular diseases
BACKGROUND In symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients, mavacamten is commercially approved to help improve left ventricular (LV) outflow tract (LVOT) gradients, symptoms, and reduce eligibility for septal reduction therapy ...
M. Desai, A. Hajj-Ali, Katy Rutkowski, S. Ospina, A. Gaballa, M. Emery, C. Asher, Bo Xu, M. Thamilarasan, Z. Popović   +9 more
semanticscholar   +1 more source

Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy

Annals of Internal Medicine, 2019
Mavacamten, an orally administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic cardiomyopathy (oHCM).To characterize the effect of mavacamten on left ventricular outflow tract (LVOT) gradient.Open-label, nonrandomized, phase 2 trial. (ClinicalTrials.gov: NCT02842242).5 academic
Stephen B, Heitner, Daniel, Jacoby, Steven J, Lester, Anjali, Owens, Andrew, Wang, David, Zhang, Joseph, Lambing, June, Lee, Marc, Semigran, Amy J, Sehnert   +9 more
openaire   +2 more sources

Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data.

Mayo Clinic proceedings
OBJECTIVE To examine the association of mavacamten therapy with cardiovascular outcomes compared with standard medical management in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Nirav Patel, M. Gaonkar, A. Pampana, N. Shetty, N. Vekariya, Peng Li, G. Arora, P. Arora   +7 more
semanticscholar   +1 more source

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks

Journal of Clinical Medicine
Background/Objectives: Mavacamten is a first-in-class cardiac myosin inhibitor approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). Long-term data regarding its real-world safety and effectiveness are limited. We aimed
Nosheen Reza, Anandkumar Dubey, N. Mahmud, Melissa A. Austin, Estherland Duqueney, Parth S. Patel, E. Boakye, Amy B. Marzolf, Nicole Hornsby, A. D. de Feria, Thomas Carattini, P. Schuler, A. Owens   +12 more
semanticscholar   +1 more source

Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten

Expert Opinion on Pharmacotherapy
Introduction Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disorder characterized by asymmetric left ventricular hypertrophy and increased risk of sudden cardiac death. While current treatments like beta-blockers, calcium channel
D. Maheta, S. Agrawal, W. Aronow
semanticscholar   +1 more source